ClinicalTrials.gg

Neuralgia, Postherpetic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 197 studies for Neuralgia, Postherpetic across more than 10 countries. 29 are recruiting or about to start. 145 of them are mainly about Neuralgia, Postherpetic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
129
Recruiting
18
Status unknown
16
Terminated
16
Not yet recruiting
10
Withdrawn
4

Phase

Phase 2
68
Phase 3
26
Phase 4
20
Phase 1
14
Early Phase 1
1

Where

United States
60
China
31
Germany
20
Korea, Republic of
14
United Kingdom
12
Japan
11

Who develops what

Add Neuralgia, Postherpetic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 4 companies, 4 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Neurodawn Pharmaceutical, Hypera Pharma and Ono Pharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PregabalinRecent, repeated
Evidence
  • NCT07758920 · Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Phase 2 · live · comparator · “Pregabalin capsule” · registered Aug 2026
  • NCT07275762 · Neurodawn Pharmaceutical Co., Ltd. · Phase 2 · live · comparator · “Pregabalin” · registered Nov 2025
  • NCT01713426 · astellas pharma · Phase 4 · comparator · “Pregabalin” · registered Oct 2012
  • NCT01688947 · Knoa Pharma · Phase 2 · comparator · “Pregabalin capsules” · registered Sep 2012
  • NCT01058642 · Merck & Co., Inc · Phase 2 · comparator · “Pregabalin” · registered Jan 2010
Viatris Inc.63% of its industry studiesUS: off-patent, 23 generics marketedEU: off-patent, 4 generics authorized22 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jun 2027 est.HL-1186 · Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Phase 2 main aim+ HL-1186 vs PregabalinNCT07758920 A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia — primary endpoint: Change in the Average Daily Pain Score (ADPS) from baseline after 12 weeks of administration · 200 enrolled
  • 1 Jun 2027 est.Pregabalin · hypera pharma · Phase 3 named, not the main aimNCT07712913 Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia — primary endpoint: Difference in the mean pain intensity score 16 weeks after the start of treatment, compared to baseline · 348 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Neuralgia, Postherpetic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 6 · Opioids 6 · NSAIDs 3

Coming up

7studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7, phase 3 first

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (11%) take healthy volunteers.

Recruiting studies that take each age, of 18
AgeWomenMen
100 (0%)0 (0%)
1813 (72%)13 (72%)
3016 (89%)16 (89%)
4017 (94%)17 (94%)
5018 (100%)18 (100%)
6517 (94%)17 (94%)
7516 (89%)16 (89%)
8510 (56%)10 (56%)

Across all 197 studies, recruiting or not: 12% stop at 75 or younger and 4% at 65; 2% take children; 0% are for women only and 2% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neuralgia, Postherpetic studies take

Of 12 phase 2 interventional studies under Neuralgia, Postherpetic, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 212 mo9–17 · 12 studies——
Interventional, no phase16 mo10–35 · 32 studies—16 mo10–35 · 30 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 197. Browse all 197 → or search them.